The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
The use of nanotherapy based on siRNA, targeting specifically the molecular JAK1/JAK3, is a new approach to treat inflammatory bowel diseases. This innovative medicine will deliver a targeted and local therapy directly to the inflamed gut, through the gastrointestinal tract.
Sparks & Co is work package leader for this project.